EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors

Ting Yan, Lun Yu, Dangang Shangguan, Wei Li, Ni Liu, Yun Chen, Yilan Fu, Jingyi Tang, Dehua Liao

International Immunopharmacology · 2023-02 · 115 · 109638

DOI: 10.1016/j.intimp.2022.109638 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023-02. Verfasst von Ting Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 41001…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) are a group of drugs designed to improve the therapeutic effects on various types of malignant tumors. Irrespective of monotherapy or combinational therapies as first-line and later-line therapy, ICIs have achieved benefits for various tumors. Programmed cell death protein-1 (PD-1) / ligand 1 (PD-L1) is an immune checkpoint that suppresses antitumor immunity, especially in the tumor microenvironment (TME). PD-1/PD-L1 immune checkpoint inhibitors block tumor-related downregulation of the immune system, thereby enhancing antitumor immunity. In comparison with traditional small-molecule drugs, ICIs exhibit pharmacokinetic characteristics owing to their high molecular weight. Furthermore, different types of ICIs exhibit different pharmacodynamic characteristics. Hence, ICIs have been approved for different indications by the Food and Drug Administration (FDA) and National Medical Products Administration (NMPA). This review summarizes pharmacokinetic and pharmacodynamic studies of PD-1/ PD-L1 inhibitors to provide a reference for rational clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsHumansB7-H1 AntigenProgrammed Cell Death 1 ReceptorImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

PD-1PD-L1PharmacodynamicPharmacokinetic

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410011, China.
  • Department of PET-CT Center, Chenzhou NO.1 People's Hospital, Chenzhou 423000, China.
  • Department of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410011, China. Electronic address: liaodehua1125@126.com.

Zitieren

APA

Yan, T., Yu, L., Shangguan, D., Li, W., Liu, N., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2023). Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. International Immunopharmacology, 115, 109638. https://doi.org/10.1016/j.intimp.2022.109638

Vancouver

Yan T, Yu L, Shangguan D, Li W, Liu N, Chen Y, et al. Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. International Immunopharmacology. 2023;115:109638. doi:10.1016/j.intimp.2022.109638

BibTeX
@article{Yan2023,
  author = {Yan, Ting and Yu, Lun and Shangguan, Dangang and Li, Wei and Liu, Ni and Chen, Yun and Fu, Yilan and Tang, Jingyi and Liao, Dehua},
  title = {Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors},
  journal = {International Immunopharmacology},
  year = {2023},
  volume = {115},
  pages = {109638},
  doi = {10.1016/j.intimp.2022.109638}
}
Kostenlos starten →